title: DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
authors.affiliation: Internal Medicine D and Obesity Clinic, Hasharon Hospital, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel. daniel3@013.net
authors.forename: Dror
authors.initials: D
authors.lastname: Dicker
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004151:Dipeptides / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D012307:Risk Factors; D000077597:Vildagliptin
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D009570:Nitriles; D011759:Pyrrolidines; C502994:saxagliptin; D000077597:Vildagliptin; D000218:Adamantane